Modeling of B16 Melanoma in Dicer1 Transgenic Mice

doi:10.3969/j.issn.1674-5817.2015.04.006

Abstract

Abstract: Objective To establish a model of B16 melanoma model in Dicer1 transgenic mice. Methods B16 melanoma cell were subcutaneously implanted into Dicer1 transgenic and C57BL/6J mice, the morphology and growth velocity of the tumor were observed. Result Compared with the contrast group, the tumor formation time in Dicer1 transgenic mice is shorter, the tumor growth rate is faster, the tumor volume is bigger (P<0.05). Conclusion The model of B16 melanoma model was successfully established in transgenic mice and the Dicer1 had significant effects on B16 melanoma bearing of mice.

Key words: Dicer1, Transgenic mice, Melanoma

CLC Number:

Q95-33

LI Zhao-yang, JIANG Chuan, GUO Xiao-chong, YANG Wei, DONG Wan-wei, ZHENG Zhi-hong. Modeling of B16 Melanoma in Dicer1 Transgenic Mice[J]. Laboratory Animal and Comparative Medicine, 2015, 35(4): 294-297.

References

[1] Maio M. Melanoma as a model tumour for immuno-oncology[J]. Ann Oncol, 2012, 23(Suppl 8):viii10-viii4.
[2] Spagnolo F, Queirolo P.Upcoming strategies for the treatment of metastatic melanoma[J]. Arch Dermatol Res, 2012, 304(3):177-184.
[3] 斯璐, 郭军. 新版中国黑色素瘤诊治指南解读[J]. 临床肿瘤学杂志, 2012, 17(2):172-173.
[4] Thompson JF, Scolyer RA, Kefford RF.Cutaneous melanoma[J]. Lancet, 2005, 365(9460):687-701.
[5] Kaufman HL.Vaccines for melanoma and renal cell carcinoma[J]. Semin Oncol, 2012, 39(3):263-275.
[6] Levy C, Khaled M, Robinson KC, et al.Lineage-specific transcriptional regulation of Dicer1 by MITF in melanocytes[J]. Cell, 2010, 141(6):994-1005.
[7] Ma Z, Swede H, Cassarino D, et al.Up-regulated Dicer1 expression in patients with cutaneous melanoma[J]. PLoS One, 2011, 6(6):e20494.
[8] Sand M, Gambichler T, Sand D, et al.Immunohistochemical expression patterns of the microRNA-processing enzyme Dicer1 in cutaneous malignant melanomas, benign melanocytic nevi and dysplastic melanocytic nevi[J]. Eur J Dermatol, 2011, 21(1):18-21.
[9] Fidler IJ.Selection of successive tumor lines for metastasis[J]. Nat New Biol,1973, 242(118):148-149.
[10] Fidler IJ.Biological behavior of malignant melanoma cells correlated to their survival in vivo[J]. Cancer Res, 1975, 35(l):218-224.
[11] 赵军, 李辰. 小鼠眼内移植3种B16小鼠黑色素瘤细胞系的比较研究[J]. 中国病理生理杂志, 2003, 19(7):914-916.
[12] Zhang L, Huang J, Yang N, et al.microRNAs exhibit high frequency genomic alterations in human cancer[J]. Proc Natl Acad Sci USA, 2006, 103(24):9136-9141.
[13] Mueller DW, Rehli M, Bosserhoff AK, et al.miRNA expression profiling in melanocytes and melanoma cell lines reveals miRNAs associated with formationand progression of malignant melanoma[J]. J Invest Dermatol, 2009, 129(7): 1740-1751.
[14] Stark MS, Tyagi S, Nancarrow DJ, et al.Characterization of the melanoma miRNAome by deep sequencing[J]. PLoS One, 2010, 5(3):e9685.
[15] Caramuta S, Egyhazi S, Rodolfo M, et al.MicroRNA expression profiles associated with mutational status and survival in malignant melanoma[J]. J Invest Dermatol, 2010,130(8):2062-2070.
[16] Segura MF, Belitskaya-Levy I, Rose AE, et al.Melanoma MicroRNA signature predicts post-recurrence survival[J]. Clin Cancer Res, 2010, 16(5):1577-1586.
[17] Hammond SM.Dicing and slicing: the core machinery of the RNA interference pathway[J]. FEBS Lett, 2005, 579(26):5822-5829.